technology
Mammalian Display
Beyond affinity: developability as key to success
Our Mammalian Display is a proprietary clinically validated technology allowing the generation of abundant therapeutic antibody leads with excellent developability properties.
About the tecnhology
Mammalian Display
Mammalian Display is a proprietary technology that enables the construction of large libraries of stable cell lines displaying human antibodies on their surface. As well as generating an abundance of therapeutic antibody leads, our technology addresses developability issues early in discovery, increasing the likelihood of successful progress through the development process.
The platform uses gene editing technology to efficiently direct site-specific integration of antibody genes into a single locus within the mammalian cell genome. This enables multi-parametric FACS selection and identification of the best molecules from tens of millions of antibodies in their final therapeutic format: from typical IgG, to VHH, bispecific, CAR and TCR. The display level of antibodies in this system is uniquely correlated with their biophysical properties in solution and late-stage developability and the technology is suitable for engineering of antibodies with high affinities and/or improved developability profiles.
Get to know
Mammalian Display’s differentiating aspect on developing the right antibody
Screening performed by FACS allowing for large library sizes to be screened for binding and antibody presentation level
Full IgG antibodies displayed in surface of mammalian display thereby removing the need for IgG reformatting
From standard IgG to VHH, VHH-Fc, bispecifics, antibody fusions, CAR and TCR
Allows for mammalian post translational modifications within a mammalian cell background
Site specific integration into a single locus results in transcriptional normalization allowing for comparative display analysis - higher display associates with better developability
Different strategies available to select for epitope specificity (high diversity)
Selection as IgG facilitates standard affinity measurements
Licensing Opportunity For Your Project’s Success
The Mammalian Display is also accessible under a licensing model structure. The internalization of this technology encourages innovation and technology diversification onto your therapeutic lead candidate research. This will ultimately mitigate the risk of clinical failure and speed your pipeline to the market.
Our technology transfer offers a range of support to ensure the effective integration and operation of the Mammalian Display in your internal workflows. The licensing of Mammalian Display also encompasses improvements to the platform and we welcome collaborative developments to address your specific needs.
